Kevin O’Leary: We’ve got a political situation brewing in Canada

Trade and Tariffs

🌎 Q: How is the US-China trade war affecting global trade relations?
A: The US trade team is in contact with over 200 countries, prioritizing key partners like Canada, Mexico, and the EU, with potential tariff rates of 10-15% for countries outside China if no agreements are reached by midnight.

🇨🇦 Q: What's causing uncertainty in the Canadian market?
A: Recent statements on Gaza by the Canadian government have angered Trump, leading to market volatility and concerns over Canada's 35% tariff rate.

Pharmaceutical Industry

💊 Q: How is Trump addressing high drug prices?
A: President Trump has sent letters to 17 pharmaceutical CEOs demanding they cut prices on prescribed medications, implementing a form of price control.

Technology and AI

🤖 Q: What's the main challenge for big tech companies in the coming years?
A: The real question for companies like Microsoft and Google is whether their AI capabilities will be able to generate profits over the next 5 years.

📈 Q: How have big tech stocks been performing recently?
A: Big tech companies like Microsoft and Google have had a fantastic run in recent years, with their stocks performing well.

International Trade

🇨🇭 Q: What's the current situation with Swiss tariffs?
A: The Swiss tariff rate is currently at 10% but is expected to rise to 39% if no solution is found, exemplifying how small political trade issues are causing market fluctuations.

Market Dynamics

🌐 Tariff stability of 10-15% exists for countries with agreements, but Canada faces uncertainty due to its Gaza statements, causing market volatility.

📊 The Chinese market is currently outside the 10-15% stability range, while other markets are expected to remain within it, according to Kevin O'Leary.

Pharmaceutical Industry

💊 Pharmaceutical companies have been subject to price controls for decades, consistently arguing that high prices are necessary to fund research and development.

🏛️ US President Trump has sent letters to 17 CEOs of pharmaceutical companies, demanding lower prices as part of ongoing price control measures.

Technology Sector

🚀 Big tech companies like Microsoft and Google have experienced a "fantastic run" for years, with focus now shifting to whether AI can generate profits over the next 5 years.

International Trade

🇨🇭 Switzerland faces a potential tariff increase from 10% to 39% if they fail to resolve their trade situation, highlighting a significant trade policy issue.

• 00:00 📣 The White House is set to notify countries about tariff deadlines through a letter or executive order by midnight, prioritizing major trading partners after extensive outreach efforts.
• 00:33 💡 Kevin O'Leary attributes the market's sell-off to uncertainty surrounding Canada, a major trading partner, due to a brewing political situation.
• 01:25 💸 Canada's political situation is causing market concern, with potential trade implications, and a resolution is hoped for within 24 hours to avoid a significant economic hit.
• 01:53 💡 Canada faces a 35% situation, unlike previous 10-15% rates that were considered good, causing market fluctuations amid a brewing political situation.
• 02:10 💸 Kevin O'Leary disputes the pharmaceutical industry's claim that high drug prices are necessary to fund research and development, calling it a perpetual excuse.
• 02:47 💸 Kevin O'Leary discusses the Canadian political situation and pharmaceutical industry, noting that Trump's claim to lower drug prices seems unlikely given the industry's history and big tech's influence.
• 03:33 💡 Kevin O'Leary remains long on big tech and cryptocurrencies, focusing on AI's profit potential over the next five years as the key market concern.

WatchUrl: https://www.youtube.com/watch?v=Ve_KyCo9hMU